NORTH CHICAGO, Ill. - AbbVie (NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, announced they will present 12 abstracts and two late-breaking presentations during the 2022 American Academy of Dermatology (AAD) Annual Meeting, March 25-29, in Boston. Data across AbbVie and Allergan's diversified portfolio of medical and aesthetic dermatology products underscore the companies' deep-rooted commitment to advancing science and striving to redefine the standards of patient care.

AbbVie will present new research on the efficacy, durability and safety of RINVOQ (upadacitinib) and SKYRIZI (risankizumab-rzaa). Notable data will include a post-hoc analysis from the Heads Up study evaluating the degree and distribution of skin improvement from baseline with RINVOQ versus DUPIXENT (dupilumab) in adults with moderate to severe atopic dermatitis. Additionally, AbbVie will present an interim analysis from the LIMMitless open-label extension trial investigating continuous SKYRIZI treatment beyond 4.5 years in adults with moderate to severe plaque psoriasis, as well as new real-world findings from the CorEvitas Psoriasis Registry, including patient reported outcomes with SKYRIZI in adults with moderate to severe plaque psoriasis.

'We look forward to presenting data at AAD that demonstrate our leadership in and commitment to advancing research across a myriad of dermatologic conditions,' said Celine Goldberger, M.D., vice president, head of U.S. medical affairs, AbbVie. 'Science is at the core of our work, helping us in our commitment to improve the care of patients with serious immune-mediated conditions now and for years to come.'

Allergan Aesthetics has one of the most researched portfolios in the aesthetics industry and will spotlight a novel hydrating serum. Additionally, the company will share results from a multicenter and randomized controlled study evaluating the safety and effectiveness of hyaluronic acid (HA) injectable gel for restoring jawline definition as well as data on the effectiveness and safety of onabotulinumtoxinA for the treatment of masseter muscle prominence.

'Our research and development team is focused on driving innovation to provide the most comprehensive, science-based product offerings that will continue to help advance aesthetic medicine,' said Darin Messina, senior vice president, Allergan Aesthetics R&D. 'We are proud to share our learnings and engage with the larger medical community at AAD.'

About RINVOQ (upadacitinib)

Discovered and developed by AbbVie scientists, RINVOQ is a selective JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.1 Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3, and TYK-2.2 The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.

In the U.S., RINVOQ is approved for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers as well as adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.2 RINVOQ is approved for use in adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. RINVOQ is approved for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. In the EU, RINVOQ is approved for the treatment of adults with moderate to severe active rheumatoid arthritis, adults with active psoriatic arthritis and adults with active ankylosing spondylitis. RINVOQ is also approved in the EU for adults and adolescents with moderate to severe atopic dermatitis.

Phase 3 trials of RINVOQ in rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.3-10

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.

About Allergan Aesthetics

Allergan Aesthetics, an AbbVie company, develops, manufactures, and markets a portfolio of leading aesthetics brands and products. Their aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Their goal is to consistently provide customers worldwide with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. www.AllerganAesthetics.com

AbbVie Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ('Allergan'), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, 'Risk Factors,' of AbbVie's 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Contact:

AbbVie US Media

Stephanie Tennessen

T: +1 (224) 214-8638

E: Stephanie.Tennessen@abbvie.com

(C) 2022 Electronic News Publishing, source ENP Newswire